AzurRx BioPharma (NASDAQ:AZRX) has been given a $8.00 price target by HC Wainwright in a note issued to investors on Friday. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 139.52% from the stock’s current price.
AzurRx BioPharma (NASDAQ AZRX) traded down $0.07 on Friday, reaching $3.34. The company’s stock had a trading volume of 28,543 shares, compared to its average volume of 64,151. AzurRx BioPharma has a 52 week low of $2.40 and a 52 week high of $5.25.
AzurRx BioPharma (NASDAQ:AZRX) last posted its quarterly earnings results on Monday, November 13th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.13). equities research analysts forecast that AzurRx BioPharma will post -1.05 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/20/azurrx-biopharma-azrx-pt-set-at-8-00-by-hc-wainwright.html.
About AzurRx BioPharma
AzurRx BioPharma, Inc is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101.
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.